[Multidisciplinary treatment for small cell lung cancer].
The effect of multidisciplinary treatment of small cell carcinoma of the lung was tested. The response rates to induction chemotherapy were 69.2% (9/13) and 57.1% (12/22) in small cell carcinoma of the lung with limited and extensive disease, respectively. The response rates of oat and intermediate cells were 63.6% (14/22) and 50% (5/10), respectively. Radiation therapy to primary site and mediastinum after induction chemotherapy was also effective, producing the response rates of 87.8% (7/8) and 58.3% (7/12) in limited disease and extensive disease, respectively. The non-responder and recurrent cases responded to chemotherapy with epipodophyllotoxin and/or cisplatin but not with mitomycin C and/or adriamycin. The median survival of all 37 cases was 12.2+ months, and those with limited and extensive cases were 14.8+ and 8.7 months, respectively.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D008937:Mitomycins; D009607:Nitrosourea Compounds; D015376:Nimustine; D016685:Mitomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin